
Name: | Dexamethasone 17-Ketone |
Catalogue No. | VE005887 |
CAS No. | N/A |
Molecular Formula | C20H25FO3 |
Molecular Weight | 332.42 |
Status | In-stock |
IUPAC Name | (8S,9R,10S,11S,13S,14S)-9-fluoro-11-hydroxy-10,13,16-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro- |
Appearance | White Powder |
Description | Dexamethasone 17-Ketone or (8S,9R,10S,11S,13S,14S)-9-fluoro-11-hydroxy-10,13,16-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro- is a degradation product of Dexamethasone which is the first compound to extensively better the survival in an RCT in COVID-19 patients. It is also an extensively used drug that is widely evaluated and cost-effective. |
References | Kane, Michael P., and Kiyoshi Tsuji. “Radiolytic Degradation Scheme for 60Co-Irradiated Corticosteroids.” Journal of Pharmaceutical Sciences, vol. 72, no. 1, Jan. 1983, pp. 30–35,https://doi.org/10.1002/jps.2600720108.Lammers, Twan, et al. “Dexamethasone Nanomedicines for COVID-19.” Nature Nanotechnology, vol. 15, no. 8, Aug. 2020, pp. 622–24,https://doi.org/10.1038/s41565-020-0752-z. |